Following immunization with XBB.1.5 vaccines, patients with CLD had comparable anti-RBD IgG serum levels and ACE2 binding inhibition to non-anti-TNF-treated patients with IBD (p > 0.999 for all tested SARS-CoV-2 lineages; Figure S4). Here, ACE2 is linked to inflammatory bowel disease.